55326-07-3

Basic information

• Product Name: 1,3,6-Trimethyl-5-nitrouracil
• Synonyms: 5-NITRO-1,3,6-TRIMETHYLURACIL
• CAS NO: 55326-07-3
• Molecular Formula: C₇H₉N₃O₄
• Molecular Weight: 199.17
• Mol File: 55326-07-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 273.2 °C at 760 mmHg
• Flash Point: 119 °C
• Appearance: /
• Density: 1.43 g/cm³
• Vapor Pressure: 0.00582mmHg at 25°C
• Refractive Index: 1.575
• CAS DataBase Reference: 1,3,6-Trimethyl-5-nitrouracil(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3,6-Trimethyl-5-nitrouracil(55326-07-3)
• EPA Substance Registry System: 1,3,6-Trimethyl-5-nitrouracil(55326-07-3)

Safety Data

• Hazardous Substances Data: 55326-07-3(Hazardous Substances Data)

Usage

General Description

1,3,6-Trimethyl-5-nitrouracil, also known as TMTNU, is a chemical compound belonging to the class of uracil derivatives. It is a potent antithyroid agent and a competitive inhibitor of thyroid peroxidase which plays a key role in the synthesis of thyroid hormones. TMTNU has been primarily studied for its potential use in the treatment of hyperthyroidism and thyroid cancer. It has been shown to effectively reduce the production of thyroid hormones by inhibiting the uptake of iodide in the thyroid gland. Additionally, TMTNU has demonstrated anti-cancer properties by inhibiting the growth of thyroid cancer cells. However, due to its potential toxicity and side effects, further research is needed to determine its safety and efficacy for clinical use.

InChI:InChI=1/C7H9N3O4/c1-4-5(10(13)14)6(11)9(3)7(12)8(4)2/h1-3H3

Upstream product

• 16632-21-6 5-nitro-6-methyluracil 
• 77-78-1 dimethyl sulfate 
• 38500-84-4 3,6-dimethyl-5-nitro-1-(p-nitrophenyl)uracil 
• 74-89-5 methylamine 
• 37412-30-9 3,6-dimethyl-1-phenyluracil 
• 19674-60-3 3,6-dimethyluracil 
• 626-48-2 6-Methyluracil 
• 13509-52-9 1,3,6-trimethyluracil 

Downstream Products

• 1366000-20-5 N-(2,4-difluoro-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-19-2 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(3-iodo-phenyl)-acetamide 
• 1366000-43-2 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-[4-(4-hexyl-phenyl)-thiazol-2-yl]-acetamide 
• 1366000-18-1 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d ]pyrimidin-5-yl)-N-(4-iodo-phenyl)-acetamide 
• 1366000-17-0 N-(4-chloro-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-14-7 (1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetic acid 
• 1366000-35-2 N-benzyl-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-33-0 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-morpholin-4-yl-phenyl)-acetamide 
• 1366000-32-9 N-(4-cyclohexyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-31-8 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-hexyl-phenyl)-acetamide 
• 1366000-30-7 N-(4-butyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-29-4 N-(4-tert-butyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 
• 1366000-28-3 2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-N-(4-isopropyl-phenyl)-acetamide 
• 1366000-27-2 N-(4-benzylsulfamoyl-phenyl)-2-(1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-pyrrolo[3,2-d]pyrimidin-5-yl)-acetamide 

Relevant articles and documents

The impact of 5-substituted uracil derivatives on immortalized embryo lung cells

Background: Pyrimidine-based drugs stimulate tissue regeneration and immunity, two components that need to be improved in a number of respiratory diseases of different etiology (e.g. influenza and asthma). In the present study we investigated relationships between the character of substitutions in the uracil structure and the impact of the respective uracil derivatives on the immortalized lung cells. Methods: The level of cell proliferation, maximum tolerated dose and toxic effect of 5-substituted uracil derivatives (12 compounds) were studied on the immortalized lung epithelial cells and compared with the ones of 6-methyluracil. Results: 5-Carboxyuracil and 1,3-dimethyl-5-carboxyuracil had the lowest cytotoxicity among the studied compounds. Their maximal tolerated dosage values were 5 times higher whereas the proliferation index was increased by 25% and 75%, respectively, compared to 6-methyluracil, known for its positive effects on cell regeneration. Conclusion: 5-Carboxyuracil and 1,3-dimethyl-5-carboxyuracil have the best perspectives for further studies on their biological effects.

FUSED PYRIMIDINE-DIONE DERIVATIVES AS TRPA1 MODULATORS

The invention described herein relates to novel fused pyrimidinediones derivatives of formula (I) which are TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPAl (Transient Receptor Potential subfamily A, member 1). This invention also provides processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPAl. Formula (I)

A2B ADENOSINE RECEPTOR ANTAGONISTS

Disclosed are novel compounds that are A2B adenosine receptor antagonists having the following structure (I) wherein R1 and R2 are independently chosen from hydrogen, optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, and R4 is an optionally substituted heteroaryl moiety. The compounds of the invention are useful for treating various disease states, including asthma, chronic obstructive pulmonary disorder, pulmonary inflammation, emphysema, diabetic disorders, inflammatory gastrointestinal tract disorders, immunological/inflammatory disorders, cardiovascular diseases, neurological disorders, and diseases related to angiogenesis.